Daktari Biotechnology Ltd is inviting FOUNDER ANGEL INVESTORS to join in advancing the progress of medicines and vaccines in Kenya. The Founder Angel Investors will take up 3 million shares of Ksh 500 (About $4). The minimum angel investment is 100 shares of Ksh 50,000 (About $400).
Kenya and Africa life expectancy is below 70 years because of lack of medicines and vaccines.
Africa's population of 1.4 billion is expected to grow and reach 2 billion. This is a huge market for medicine and vaccines. Daktari Biotechnology Ltd goal is to produce medicines and vaccines for this African population.
As the World GDP grew to $106 trillion (2024), the medicine and vaccines revenue grew to about $2 trillion. The World’s 50 Largest Pharmaceutical Companies received about $1 trillion of this revenue. Their market valuation is $4.7 trillion.
Daktari Biotechnology Ltd will be part of growing Africa's GDP from its current $3 trillion to $20 trillion by 2075. The Africa medicines and vaccines market will grow to about $400 billion.
Daktari Biotechnology Ltd goal is to achieve a revenue of 5% of the $400 billion Africa market (About $20 billion, KES 2 trillion). On achieving this the Daktari Biotechnology shares could reach a value of $40 billion. The 3 million shares taken by Founder Angel Investors could have a value $3 billion, about Ksh 300 billion. This is a growth from Ksh 500 to 100,000 in 50 years.
FILL IN THE INVESTMENT FORM BELOW
CALL TO INVEST 31st March 2025 TO 2ND May 2025
Call / WhatsApp:
Dr. Wilson Endege: +1 (781) 492-6851 (Founder, Daktari Biotechnology)
Daktari Biotechnology: +254 113 217 148 (Voi Office)
Daktari Biotechnology Ltd is located at Diaspora University Town where it is building the Medicine and Vaccine plant at an 11 acre plot.
The company will also build 3 properties for its pharmaceutical business line. The company will open 6 Pharmacies in Diaspora University Town.
As Diaspora University Town GDP reaches Ksh 15 billion a medicine and vaccine market of Ksh 500 million will be created.
Architect Prof. David Ogoli is the designer of the plot and medicine and vaccine building. 80% of the investment by angel investors will fund the plant building and equipment installed.
The Scientists founding Daktari Biotechnology Ltd are also part of the founding team of the Diaspora University departments for teaching and research.
JOBS, PHARMACIES, PRODUCT PRODUCTION, REVENUE, EXPENSES, PROFITS & DIVIDENDS
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Jobs | 20 | 100 | 200 | 400 | 1,000 |
| Pharmacies | 3 | 10 | 30 | 60 | 100 |
| Product Prod | - | 1,000,000 | 10,000,000 | 100,000,000 | - |
| Revenue (KES) | 50,000,000 | 100,000,000 | 1,000,000,000 | 4,000,000,000 | 20,000,000,000 |
| Expenses | 30,000,000 | 60,000,000 | 600,000,000 | 2,400,000,000 | 12,000,000,000 |
| Gross Profit | 20,000,000 | 40,000,000 | 400,000,000 | 1,600,000,000 | 8,000,000,000 |
| Tax | 6,000,000 | 12,000,000 | 120,000,000 | 480,000,000 | 2,400,000,000 |
| Net Profit | 14,000,000 | 28,000,000 | 280,000,000 | 1,120,000,000 | 5,600,000,000 |
| Retained | 14,000,000 | 28,000,000 | 180,000,000 | 620,000,000 | 3,600,000,000 |
| Dividend | 0 | 0 | 100,000,000 | 500,000,000 | 2,000,000,000 |
| Dividend/Share | - | 10 | 50 | 200 | - |
Daktari Biotechnology’s plans and operational milestones outline the strategic steps necessary to achieve scalable production, market penetration, and sustainable growth. These milestones are set with realistic, time-bound goals that reflect the company’s commitment to operational excellence. Each milestone is designed to ensure that DKTB remains focused on its mission to deliver high-quality, affordable healthcare solutions across Africa while scaling efficiently and maintaining the highest standards of quality control.
| Milestone | Objective | Timeline |
|---|---|---|
| 1. Facility, Construction, Completion & Equipment Installation | Establish state-of-the-art production and research facilities with cutting-edge technology and equipment. | Q1 – Q4, 2025 |
| 2. DKTB Care Pharmacies | Establish and Launch 8-Regional Compounding Pharmacies | Q2 2025 – Q4 2025 |
| 3. Biotechnology & Biochemistry Plans | Development and launch of DUT/DKTB Biotechnology/Biochemistry Plans | Q3 – Q4 2025 |
| 4. Launch of E-commerce Platform | Develop and launch an e-commerce platform for direct sales to healthcare providers and consumers. | Q3, 2025 |
| 5. Product Development & Initial Trials | Complete development of seminal core products (long-acting anti-Malaria, anti-HIV & East Coast Fever drugs plus a FMDV Vaccine). | Q4, 2026 |
| 6. Regulatory Approval & Compliance Certification | Obtain GMP certification and necessary regulatory approvals for core products in East African markets. | Q4, 2027 – Q4, 2028 |
| 7. Strategic Distribution Partnerships | Secure partnerships with key regional distributors and healthcare providers across East, Central, and West Africa. | Q4, 2028 – Q4, 2029 |
| 8. First Product Launch in East Africa | Release of the first batch of core products to the East African market. | Q4, 2029 |
| 9. Expansion to West & Central African Markets | Scale distribution network to West and Central Africa, leveraging strategic partnerships for market entry. | Q4, 2029 – Q4, 2030 |
| 10. Establishment of Cold Chain Logistics Network | Develop a robust cold chain system for safe transport of vaccines and temperature-sensitive products. | Q1 – Q3, 2029 |
| 11. Launch of Additional Product Lines | Introduce new biopharmaceuticals (e.g., anti-TB drugs, anti-Diabetes & Vaccine for NCDV). | Q4, 2029 – Q2, 2030 |
| 12. Secure Series B Funding for Expansion | Raise additional capital to support further R&D, facility expansion, and market growth initiatives. | Q3, 2029 – Q3, 2030 |
| 13. Establishment of Innovation Hub at Diaspora University Town | Create a dedicated space for biopharmaceutical R&D, fostering innovation and supporting tech transfer from academic research to marketable products. | Q1, 2030 |
| 14. Facility Expansion & Capacity Scaling | Expand production facilities to increase manufacturing capacity and meet growing market demand. | Q3, 2030 – Q2, 2031 |
| 15. Attain Full Regulatory Compliance Across Africa | Obtain regulatory certifications for all core products across key African markets. | Q1, 2031 – Q4, 2031 |
| 16. R&D Collaboration with Global Institutions | Secure research partnerships with leading global biotech firms and academic institutions to drive innovation. | Ongoing, Starting Q1, 2029 |
| 17. Market Expansion to North Africa & Middle East | Expand to North Africa and the Middle East through strategic partnerships. | Q4, 2031 – Q4, 2032 |
| 18. Achieve Profitability | Reach break-even point and achieve consistent profitability by maximizing production efficiency and sales. | Q4, 2033 |
| 19. Launch of New R&D Initiatives | Begin research on next-generation therapies tailored to emerging health challenges across the continent. | Q4, 2033 |
| 20. Full Market Coverage Across Africa | Achieve comprehensive distribution and market presence across all regions in Africa, solidifying market leadership. | Q4, 2033 |
